Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00707512 · ClinicalTrials.gov registry record
CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
A clinical trial, sponsored by Biogen.
- Terminated
- Registry status
- 87
- Enrollment target
NCT00707512 is a clinical trial that was terminated before completion, run by Biogen. The registered enrollment target is 87 participants.
The verdict
NCT00707512 was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- 87 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the incidence and pattern of serious and/or clinically significant infections, malignancies, and other serious adverse event (SAE) in participants with Crohn's Disease (CD) treated with natalizumab. The secondary objective of this study in this study population is to evaluate disease severity over time in participants with CD treated with natalizumab based on changes in the Harvey-Bradshaw Index (HBI).
Interventions
- DRUG natalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2008-06-30 |
| Est. Completion | 2015-05-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00707512
The ClinicalTrials.gov registry entry for NCT00707512 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which natalizumab is the first listed.
NCT00707512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00707512 about?
NCT00707512 is a clinical study titled "CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring". The primary objective of the study is to determine the incidence and pattern of serious and/or clinically significant infections, malignancies, and other serious adverse event (SAE) in participants with Crohn's Disease (CD) treated with natalizumab. The secondary objective of this study in this stud...
What is the current status of trial NCT00707512?
This trial is currently terminated. The enrollment target is 87 participants. The study started on 2008-06-30. Estimated completion is 2015-05-28.
What interventions are being tested in trial NCT00707512?
The interventions under investigation include: natalizumab (DRUG).
Who is sponsoring clinical trial NCT00707512?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.